https://xequel.com Xequel Bio - Pioneering the Science
Xequel Bio is transforming its proprietary aCT1 technology to develop drugs that will revolutionize the way the body responds to injury.
Xequel Bio - Pioneering the Science Please ensure Javascript is enabled for purposes of website accessibility Skip to content About About Leadership Board of Directors Pioneering the Science Technology Technology Collaborations Mechanism of Action Pipeline Pipeline Granexin Gel iNexin Ophthalmic Solution Aerosolized aCT1 News & Events News & Media Events & Presentations Careers Contact Menu About About Leadership Board of Directors Pioneering the Science Technology Technology Collaborations Mechanism of Action Pipeline Pipeline Granexin Gel iNexin Ophthalmic Solution Aerosolized aCT1 News & Events News & Media Events & Presentations Careers Contact Home Pioneering the Science People | Passion | Possibilities Pioneering the Science of Possibilities Xequel Bio is a clinical stage biopharmaceutical company transforming its proprietary alpha-connexin carboxyl-terminus 1 (aCT1) peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential. This is our Xequel. Pioneering the Science of Leadership “At Xequel, we combine the power of leadership with our personal conviction to pioneer meaningful science that ultimately impacts doctors and patients.” – Jerry St. Peter, CEO & Board Director Meet Us Pioneering the Science of Innovation Xequel Bio’s alpha-connexin carboxyl-terminus 1 (aCT1) is a new chemical entity that stabilizes gap and tight junctions and regulates inflammation at the injury site, culminating in a healthy injury response. aCT1 is an unprecedented solution that promotes healing by rebuilding healthy tissue through accelerated re-epithelialization and stabilized tissue integrity. Want to know more? Pioneering the Science of Technology Our proprietary aCT1 technology platform has extensive preclinical and clinical research to support multiple unique applications and formulations in Dermatology, Ophthalmology, and Pulmonology. Patents Obtained 0 Research Funding(NIH/DOD) $ 0 M+ Publications 0 Patients Servedin 9 clinical trials 0 + Retention within Clinical Trials 0 % Preclinical Studies 0 + Pioneering the Science for Patients We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury. Dermatology Granexin® Gel Granexin® Gel is a topical formulation of aCT1 developed to address unmet clinical needs within the field of dermatology and wound healing. Learn More Ophthalmology iNexin™ Ophthalmic Solution iNexin™ Ophthalmic Solution is an innovative formulation of aCT1 developed to address unmet needs within the field of ophthalmology focusing on corneal and retinal diseases. Learn More Pulmonology Aerosolized aCT1 Aerosolized aCT1 is a preclinical formulation being developed to address unmet needs within the field of pulmonology focusing on acute injury. Learn More Recent News Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting – Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury – – Xequel Launches New Read More » Xequel Bio Expands Leadership Team With Appointments Of Dr. Michael J. Brubaker As Chief Scientific Officer And Tony C. Tipton As Chief Operating Officer Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 – Read More » Xequel Bio Announces Positive Results From Phase 1b Study Of INexinTM, A Novel ACT1 Ophthalmic Solution Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance Read More » Pioneering the Science of People Ready to be part of something exciting and life-changing? (The best Xequels always are.) Join Our Team Pioneering the Science of People Ready to be part of something exciting and life-changing? (The best Xequels always are.) Get Started Corporate Headquarters 777 Taylor StreetSuite 1140Fort Worth, Texas 76102info@xequel.com Contact Us Research & Development 1501 Belle Isle AvenueSuite 220Mount Pleasant, South Carolina 29464843.388.3276 © 2024 Xequel Bio. All Rights Reserved. Privacy Policy | Accessibility Statement Powered by Website Muscle
en
us
en-US
1731225661
https://xequel.com
تعديل موقعك؟
ماذا تفعل؟